Moderna's mRNA Flu Vaccine Faces FDA Advisory Panel Review

SentiSense · Published · Updated

Moderna's MFLUSIVA (mRNA-1010), the first mRNA-based seasonal influenza vaccine candidate in the U.S., went before the FDA's VRBPAC advisory panel on ...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis